Frankfurt
08.09.25 | 08:12
0,083 Euro
-5,14 % -0,005
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.07. | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 3 2024/2025 | 99 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2025 - May 31, 2025. This English version of the Interim Report is a translation of the Swedish version.... ► Artikel lesen | |
| 14.07. | NEXTCELL PHARMA AB: NextCell Highlighted in FUJIFILM's Strategic Vision, According to GEN | 2 | Cision News | ||
| 13.06. | NextCell Pharma AB: All Patients Successfully Treated in ProTrans-Young Study | 347 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") announces today that all patients in the ongoing ProTrans-Young clinical trial have now successfully been treated. This milestone marks the completion... ► Artikel lesen | |
| 02.06. | NEXTCELL PHARMA AB: NextCell Pharma announces outcome of exercise of TO2 and resolves on directed share issues to guarantors | 1 | Cision News | ||
| 28.05. | NEXTCELL PHARMA AB: NextCell Pharma receives additional declarations of intent regarding exercise of TO2 | 1 | Cision News | ||
| 28.05. | NEXTCELL PHARMA AB: Angela Vollstedt joins NextCell Pharma's Board of Advisors to Strengthen Scientific and Manufacturing Strategy Ahead of Licensing Discussions | 1 | Cision News | ||
| 26.05. | NextCell Pharma AB: NextCell Receives US Patent for MSC Prediction Algorithm | 332 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") is pleased to announce the issuance of a US patent titled "MSC Prediction Algorithm" by the United States Patent and Trademark Office (USPTO). The patent... ► Artikel lesen | |
| 23.05. | NEXTCELL PHARMA AB: NextCell Pharma receives declarations of intent, subscription undertakings and top guarantees regarding exercise of TO2 | 1 | Cision News | ||
| NEXTCELL PHARMA Aktie jetzt für 0€ handeln | |||||
| 20.05. | NextCell, Fujifilm Irvine Scientific Enter Strategic Pact | 4 | Contract Pharma | ||
| 20.05. | NextCell Pharma AB: NextCell announces strategic collaboration with Fujifilm Irvine Scientific | 706 | GlobeNewswire (Europe) | NextCell Pharma AB's ("NextCell" or "the Company") has entered into a strategic collaboration with Fujifilm Irvine Scientific Inc. to bring together their core competences in mesenchymal stromal cells... ► Artikel lesen | |
| 19.05. | NEXTCELL PHARMA AB: Eric Strati Joins NextCell Pharma's Board of Advisors to Support Commercial Strategy for ProTrans | 1 | Cision News | ||
| 16.05. | NEXTCELL PHARMA AB: The exercise period for NextCell Pharma's warrants of series TO2 begins today | - | Cision News | ||
| 15.05. | NEXTCELL PHARMA AB: Eight-Year-Old Hugo - Living with Type 1 Diabetes and Participating in the ProTrans Study | 1 | Cision News | ||
| 07.05. | NEXTCELL PHARMA AB: Study published in Nature Medicine shows promising results in Alzheimer's disease - supports the development of ProTrans at NextCell | 2 | Cision News | ||
| 25.04. | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 2 2024/2025 | 112 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2024 - February 28, 2025. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report.... ► Artikel lesen | |
| 24.04. | NEXTCELL PHARMA AB: NextCell presents detailed analysis of the administrative report from ProTrans-Young | 2 | Cision News | ||
| 23.04. | NEXTCELL PHARMA AB: NextCell Presents Quarterly Report | 4 | Cision News | ||
| 15.04. | NextCell Pharma AB: NextCell CEO Mathias Svahn explains the latest results from ProTrans-YOUNG and his vision for the way forward | 134 | GlobeNewswire (Europe) | NextCell Pharma ("the company" or "NextCell") has published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discusses with Mathias questions regarding the... ► Artikel lesen | |
| 07.04. | NEXTCELL PHARMA AB: Subgroup Analysis: NextCell Presents Preliminary One-Year Results from the Older Age Group in ProTrans-Young | 1 | Cision News | ||
| 28.03. | NEXTCELL PHARMA AB: NextCell's CSO Appointed to the Board of ATMP Sweden | 5 | Cision News |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 87,45 | +0,17 % | BioNTech: Chancen in Onkologie, Sorgen im Kurs | Die Aktie von BioNTech SE notiert aktuell bei 94,73 EUR. Nach dem beispiellosen Erfolg mit dem COVID-19-Impfstoff steht das Mainzer Biotech-Unternehmen vor der Herausforderung, seine Pipeline in Onkologie... ► Artikel lesen | |
| QIAGEN | 40,520 | +0,32 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,450 | 0,00 % | Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch | ||
| EVOTEC | 5,870 | +0,24 % | Evotec-Aktie: Ist das ein wichtiges Signal? | Die Evotec-Aktie bewegt sich weiterhin auf einem sehr niedrigen Niveau; am Montag verbessert sie sich aktuell um +1,5% und steht bei rund 6,10 €. Was bei dem deutschen Biotech-Unternehmen fehlt, sind... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 31,490 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 48,050 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| 4SC | 1,005 | -2,43 % | PTA-News: 4SC AG: 4SC veröffentlicht Halbjahresbericht 2025 | DJ PTA-News: 4SC AG: 4SC veröffentlicht Halbjahresbericht 2025
Unternehmensmitteilung für den Kapitalmarkt
4SC AG: 4SC veröffentlicht Halbjahresbericht 2025
Planegg-Martinsried (pta000/08.08.2025/07:30... ► Artikel lesen | |
| VERA THERAPEUTICS | 24,750 | +2,19 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| CG ONCOLOGY | 33,690 | +1,77 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 35,940 | 0,00 % | H.C. Wainwright reiterates Buy rating on Mineralys stock, citing lorundrostat potential | ||
| ARS PHARMACEUTICALS | 10,690 | +5,95 % | Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential | ||
| PRAXIS PRECISION MEDICINES | 40,660 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| BEAM THERAPEUTICS | 19,940 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,625 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,410 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
NEXTCELL PHARMA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -5,14 % bei einem Aktienkurs von 0,083 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXTCELL PHARMA AB finden Sie auf Wallstreet Online.